Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Feb 14, 2017, 03:00 ET Le vaccin PfSPZ-Cvac de Sanaria offre un haut niveau de protection contre le paludisme lors d'une étude clinique

SOUS EMBARGO JUSQU'AU 15 février à 13h00, heure française Dans un rapport publié aujourd'hui par le magazine Nature, (Sterile protection...


Feb 14, 2017, 03:00 ET PfSPZ-CVac-Malariaimpfstoff von Sanaria erzielt in klinischer Studie hohen Schutzgrad

GESPERRT BIS 15. FEB., 13:00 UHR OSTKÜSTENZEIT In einem heute in Nature veröffentlichten Artikel (Sterile protection against human malaria by...


Feb 14, 2017, 03:00 ET La vacuna PfSPZ-CVac de Sanaria consigue un elevado nivel de protección contra la malaria en ensayos clínicos

EMBARGO HASTA EL 15 DE FEBRERO A LAS 1:00PM ET En un informe publicado hoy en Nature, (Sterile protection against human malaria by...


Feb 14, 2017, 00:24 ET Kungl. Vetenskapsakademien - The First Sjöberg Prize, Totalling 1 Million US Dollars, is Awarded for Discoveries That Have Led to New and Effective Cancer Treatments

The Royal Swedish Academy of Sciences has decided to award the Sjöberg Prize 2017 to James P. Allison, The University of Texas MD Anderson Cancer...


Feb 13, 2017, 18:56 ET Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies

- First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens...


Feb 13, 2017, 15:17 ET Micro Medical Solutions Receives CE Mark Approval for MicroStent

Micro Medical Solutions, an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced...


Feb 13, 2017, 09:08 ET XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

- Dr. Robert I. Fox and Professor Simon Bowman are world-renowned rheumatologists and experts in Sjogren's syndrome - XTL...


Feb 13, 2017, 09:02 ET National Institutes of Health Funds Schneider Children's Medical Center and International Diabetes Center Closed-Loop System Research

The Institute for Endocrinology and Diabetes at Schneider Children's Medical Center in Petah Tikva, Israel, along with the International Diabetes...


Feb 13, 2017, 08:40 ET DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...


Feb 13, 2017, 08:30 ET MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company, today announced results from a...


Feb 13, 2017, 08:30 ET Doctors Confront Children's Hospitals Over #HazardousHotDogs

Hard-hitting billboards and other advertisements are urging children's hospitals in six cities to protect patients from #HazardousHotDogs. Hot dogs...


Feb 13, 2017, 08:30 ET Berkeley Lights to Present Utility of its OptoSelect™ Technology at the Annual Advances in Genome Biology and Technology (AGBT) Meeting

Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes announced today...


Feb 13, 2017, 08:05 ET Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will highlight clinical data on...


Feb 13, 2017, 08:00 ET IV Dislodgement Is a Common Problem in Vascular Access, Clinicians Say

IV dislodgement is a near-daily problem for clinicians and their patients, according to a recent focus group of vascular access experts. The...


Feb 13, 2017, 08:00 ET RPRD Diagnostics Announces Strategic Collaboration with Children's Minnesota to Advance Clinical Pharmacogenomics

RPRD Diagnostics today announced a collaboration with Children's Minnesota dedicated to implementing a pharmacogenomic testing process. RPRD...


Feb 13, 2017, 07:00 ET AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...


Feb 13, 2017, 07:00 ET Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients

Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced preliminary...


Feb 13, 2017, 03:00 ET Acacia Pharma Announces Positive Results From its Fourth and Final Pivotal Trial of BAREMSIS™ for the Rescue Treatment of PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV - NDA to be submitted to the...


Feb 10, 2017, 08:00 ET U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner

Cancer Research UK, the world's largest not-for-profit cancer research organization, has today announced that six leading U.S. scientists are among...


Feb 10, 2017, 06:50 ET Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics") today announced that it has entered into an exclusive global licensing agreement with Seattle...